Main Article Content

Buket Altinok Gunes
Yalda Hekmatshoar
Tulin Ozkan
Sureyya Bozkurt
O.Sena Aydos
Yahya Buyukasik
Elifcan Aladag
Asuman Sunguroglu


CML, Imatinib resistance, BCR-ABL mutations, sCD-1


Chronic myeloid leukemia (CML) is a malignant hematopoietic stem cell disease resulting in the fusion of BCR and ABL genes and characterized by the presence of the reciprocal translocation t(9;22)(q34;q11). BCR-ABL, a product of the BCR-ABL fusion gene, is a structurally active tyrosine kinase and plays an important role in CML disease pathogenesis. Imatinib mesylate (IMA) is a strong and selective BCR-ABL tyrosine kinase inhibitor. Although IMA therapy is an effective treatment, patients may develop resistance to IMA therapy over time. This study investigated the possible genetic resistance mechanisms in patients developing resistance to IMA. We did DNA sequencing in order to detect BCR-ABL mutations, which are responsible for IMA resistance. Moreover, we analyzed the mRNA expression levels of genes responsible for apoptosis, such as BCL-2, P53, and other genes (SCD-1, PTEN). In a group of CML patients resistant to IMA, when compared with IMA-sensitive CML patients, a decrease in SCD-1 gene expression levels and an increase in BCL-2 gene expression levels was observed. In this case, the SCD-1 gene was thought to act as a tumor suppressor. The present study aimed to investigate the mechanisms involved in IMA resistance in CML patients and determine new targets that can be beneficial in choosing the effective treatment. Finally, the study suggests that the SCD-1 and BCL-2 genes may be mechanisms responsible for resistance.

Keywords  CML; Imatinib resistance; BCR-ABL mutations; SCD-1


Download data is not yet available.

Abstract 615
PDF Downloads 757
HTML Downloads 304


1. Meenakshi Sundaram, D.N., et al., Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options. Drug Discov Today, 2019. 24(7): p. 1355-1369.
2. Asnafi, A.A., et al., Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches. J Cell Physiol, 2019. 234(5): p. 5798-5806.
3. Cambier, N., et al., BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene, 1998. 16(3): p. 335-48.
4. Furtado, V.F., et al., Accelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase. Rev Bras Hematol Hemoter, 2015. 37(5): p. 341-7.
5. Palandri, F., et al., The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica, 2009. 94(2): p. 205-12.
6. Druker, B.J., et al., Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med, 2001. 344(14): p. 1038-42.
7. Nestal de Moraes, G., et al., The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia. Leuk Res Treatment, 2012. 2012: p. 671702.
8. Awidi, A., et al., ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan. Genet Test Mol Biomarkers, 2012. 16(11): p. 1317-21.
9. Quintas-Cardama, A. and J. Cortes, Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood, 2009. 113(8): p. 1619-30.
10. Hekmatshoar, Y., et al., The role of metabolism and tunneling nanotube-mediated intercellular mitochondria exchange in cancer drug resistance. Biochem J, 2018. 475(14): p. 2305-2328.
11. Koundouros, N. and G. Poulogiannis, Reprogramming of fatty acid metabolism in cancer. Br J Cancer, 2020. 122(1): p. 4-22.
12. Zhang, H., et al., Scd1 plays a tumor-suppressive role in survival of leukemia stem cells and the development of chronic myeloid leukemia. Mol Cell Biol, 2012. 32(10): p. 1776-87.
13. Scaglia, N. and R.A. Igal, Stearoyl-CoA desaturase is involved in the control of proliferation, anchorage-independent growth, and survival in human transformed cells. J Biol Chem, 2005. 280(27): p. 25339-49.
14. Freeman, D.J., et al., PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell, 2003. 3(2): p. 117-30.
15. Diaz-Blanco, E., et al., Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia, 2007. 21(3): p. 494-504.
16. Baccarani, M., et al., Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2006. 108(6): p. 1809-20.
17. Haznedaroglu, I.C., Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML). Mediterr J Hematol Infect Dis, 2014. 6(1): p. e2014009.
18. Hekmatshoar, Y., et al., Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms. Cell Mol Biol (Noisy-le-grand), 2018. 64(6): p. 23-30.
19. Fernandez, L.P., M. Gomez de Cedron, and A. Ramirez de Molina, Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment. Front Oncol, 2020. 10: p. 577420.
20. Chen, L., et al., Stearoyl-CoA desaturase-1 mediated cell apoptosis in colorectal cancer by promoting ceramide synthesis. Sci Rep, 2016. 6: p. 19665.
21. Tracz-Gaszewska, Z. and P. Dobrzyn, Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer. Cancers (Basel), 2019. 11(7).
22. Huang, J., et al., SCD1 is associated with tumor promotion, late stage and poor survival in lung adenocarcinoma. Oncotarget, 2016. 7(26): p. 39970-39979.
23. Presler, M., et al., Increased expression of the gene encoding stearoyl-CoA desaturase 1 in human bladder cancer. Mol Cell Biochem, 2018. 447(1-2): p. 217-224.
24. Wang, C., et al., Stearoyl-CoA desaturase 1 (SCD1) facilitates the growth and anti-ferroptosis of gastric cancer cells and predicts poor prognosis of gastric cancer. Aging (Albany NY), 2020. 12(15): p. 15374-15391.
25. Southam, A.D., et al., Drug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids. Cancer Res, 2015. 75(12): p. 2530-40.
26. Morgan-Lappe, S.E., et al., Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res, 2007. 67(9): p. 4390-8.
27. Carter, B.Z., et al., Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med, 2016. 8(355): p. 355ra117.
28. Perini, G.F., et al., BCL-2 as therapeutic target for hematological malignancies. J Hematol Oncol, 2018. 11(1): p. 65.
29. Daflon-Yunes, N., et al., Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms. Mol Cell Biochem, 2013. 383(1-2): p. 123-35.
30. Peng, C., et al., Role of Pten in leukemia stem cells. Oncotarget, 2010. 1(2): p. 156-60.
31. Panuzzo, C., et al., BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia. PLoS One, 2014. 9(10): p. e110682.